Company Filing History:
2 out of 42 
2 out of 7 Years Active: 2024-2025
Title: Pablo Gonzalez Muñoz: Innovator in Monoclonal Antibodies
Introduction
Pablo Gonzalez Muñoz is a notable inventor based in Santiago, Chile. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for diagnosing and treating herpes simplex virus infections.
Latest Patents
One of his latest patents is for a monoclonal antibody known as 14F5F6. This antibody specifically recognizes herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). The invention aims to facilitate the development of diagnostic methods for herpes simplex virus infections. Additionally, it is intended for the production of pharmaceutical compositions for the treatment and prevention of these infections. Another significant patent is for the monoclonal antibody 11B2C7, which also targets HSV-1 and HSV-2. Similar to 14F5F6, this antibody is designed to aid in diagnosis and therapeutic applications related to herpes simplex virus infections.
Career Highlights
Pablo Gonzalez Muñoz has worked with prestigious institutions such as Pontificia Universidad Catòlica De Chile and Fundación Copec Universidad Católica. His experience in these organizations has contributed to his expertise in the field of monoclonal antibodies and their applications in medicine.
Collaborations
He has collaborated with professionals in his field, including Susan Bueno Ramírez, to advance research and development in biotechnology.
Conclusion
Pablo Gonzalez Muñoz is a prominent inventor whose work in monoclonal antibodies has the potential to significantly impact the diagnosis and treatment of herpes simplex virus infections. His contributions to biotechnology reflect a commitment to innovation and improving healthcare outcomes.